Business Context and Reporting Period
This Form 8-K is a current report filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on December 23, 2021. The filing addresses Item 5.02 regarding the departure of an officer and the execution of a transition agreement.
Key Financial Metrics
The filing does not provide general financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific compensation and severance terms for the departing officer:
- Severance Payment: $100,000 (contingent on execution of a release of claims).
- Consulting Fee: $10,000 per calendar month for an 18-month period.
- Base Salary (Pre-Separation): $365,000 per year (paid until December 31, 2021).
Material Changes
The material change reported is the resignation of Wendy Johnson as Chief Business Officer, effective December 31, 2021. She was replaced in her previous role by Ashley F. Hall, J.D., who was appointed Chief Development Officer. Ms. Johnson will transition to a consultant role for 18 months following her separation date.
Outlook, Risks, and Unusual Items
Management Commentary and Arrangements:
- Equity Vesting: Ms. Johnson's stock options will continue to vest during the 18-month consulting period. Full acceleration of vesting occurs if the company terminates the consulting relationship for reasons other than her breach of agreement prior to June 30, 2023.
- Consulting Terms: The agreement includes a standard hourly rate for any consulting hours exceeding 32 hours per month.
- Documentation: The full text of the Transition, Separation and Consulting Agreement is intended to be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2021.
Risks and Contingencies: The severance payment and consulting engagement are contingent upon Ms. Johnson executing a standard release of claims.
Investor Verification Checklist
- Verify the execution of the release of claims to confirm the $100,000 severance payment obligation.
- Monitor the upcoming Form 10-K filing for the full text of the Transition, Separation and Consulting Agreement.
- Confirm the status of Ms. Johnson's equity awards and any potential acceleration triggers.
- Review the impact of the leadership transition on the company's business development strategy.